Long-term hormone therapy for perimenopausal and postmenopausal women.

Cochrane Database Syst RevSep 4, 2026 (epub)
Clinical ResearchObstetrics & GynecologyGeriatricsOpen access

Magdalena Bofill Rodriguez, Li Ning Yong, Sanja Mirkov et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the long-term effects of hormone therapy in perimenopausal and postmenopausal women, analyzing data from 24 studies with 45,660 participants. The findings suggest that combined continuous hormone therapy likely increases the risk of breast cancer (RR 1.27) and stroke (RR 1.39), while reducing the risk of clinical fractures (RR 0.78).

Key findings

  • Combined continuous hormone therapy probably increases the risk of breast cancer (RR 1.27).
  • It may increase the risk of stroke (RR 1.39) and venous thromboembolism (RR 2.03).
  • Combined therapy probably reduces the risk of all clinical fractures (RR 0.78).
  • It may increase gallbladder disease requiring surgery (RR 1.64).

Why it matters

Understanding the long-term risks associated with hormone therapy is crucial for clinicians managing menopausal symptoms and considering the overall health implications for their patients, particularly regarding cancer and cardiovascular events.

Source

PubMed · PMID 42695385Free full text on PubMed Central

Published in Cochrane Database Syst Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Obstetrics & Gynecology

Clinical ResearchOncology (Medical)

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

This phase 3 randomized clinical trial evaluated the efficacy and safety of osimertinib combined with chemotherapy versus osimertinib alone in 294 patients with advanced non-small cell lung cancer (NSCLC) harboring…

JAMASep 8, 2026Open accessRead summary
Clinical ResearchHematology

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

This phase 2 randomized trial compared azacitidine plus venetoclax to induction chemotherapy in 172 previously untreated adults with acute myeloid leukemia (AML) eligible for induction.

N Engl J MedSep 3, 2026Read summary
Clinical ResearchPsychiatry

The efficacy of modified psychodynamic psychotherapy for patients with schizophrenia-spectrum disorders in Germany: a prospective, single-centre, assessor-blinded, parallel-group, randomised controlled trial.

This randomized controlled trial evaluated the efficacy of Modified Psychodynamic Psychotherapy for Schizophrenia (MPP-S) combined with treatment as usual (TAU) in 130 outpatients with schizophrenia-spectrum disorders…

Lancet PsychiatrySep 10, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.